Relapse of Type A -Lactamase-Producing Staphylococcus aureus Native Valve Endocarditis during Cefazolin Therapy: Revisiting the Issue
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Our experience with a patient with methicillin-susceptible Staphylococcus aureus aortic native valve endocarditis, who had a relapse involving fever and positive blood culture results while receiving cefazolin, led us to evaluate this organism's ability to hydrolyze cefazolin at high inocula, a previously well-documented phenomenon. Analysis of the infecting strain disclosed a high minimum inhibitory concentration of cefazolin when a large inoculum was used, as well as rapid and complete cefazolin degradation, which was associated with regrowth in a time-kill experiment. DNA sequencing of the beta-lactamase gene showed that it was identical to that of the S. aureus type A beta-lactamase, known to efficiently inactivate cefazolin. A word of caution is given regarding the use of this antibiotic for treatment of endocarditis caused by this type of S. aureus isolate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Preparation of Genomic DNA from Bacteria
Wilson, K. (2001) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb0204s56 · Cited by 2,082 · cited 1×
“Genomic DNA was extracted by the hexadecyltrimethyl ammonium bromide method, as described elsewhere [13, 14], except for the addition of lysostaphin (5 U/mL; Sigma Chemicals).”
MethodSimplified, Accurate Method for Antibiotic Assay of Clinical Specimens
Bennett, J. V., Brodie, J. L., Benner, E. J., & Kirby, W. (1966) · Applied Microbiology · doi:10.1128/aem.14.2.170-177.1966 · Cited by 955 · cited 1×
“Cefazolin concentrations were determined by agar-well diffusion bioassay using Bacillus subtilis in triplicates [11].”
MethodWilson, W. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530210060032 · Cited by 492
Pacemaker infective endocarditis
Cacoub, P., Leprince, P., Nataf, P., Hausfater, P., Dorent, R., Wechsler, B., Bors, V., Pavie, A., Piette, J. C., & Gandjbakhch, I. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00365-8 · Cited by 314 · cited 1×
“with intracardiac leads [18], did not reveal any vegetations”
BackgroundWilson, W. R. (1995) · JAMA · doi:10.1001/jama.274.21.1706 · Cited by 288
Malathum, K., Singh, K. V., Weinstock, G. M., & Murray, B. E. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.211-215.1998 · Cited by 104 · cited 1×
“Genomic DNA was extracted by the hexadecyltrimethyl ammonium bromide method, as described elsewhere [13, 14], except for the addition of lysostaphin (5 U/mL; Sigma Chemicals).”
MethodSelf-citationCharacterization of four beta-lactamases produced by Staphylococcus aureus
Zygmunt, D. J., Stratton, C. W., & Kernodle, D. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.440 · Cited by 102 · cited 1×
“However, we should also point out that cefazolin is relatively stable in the presence of type B and C b-lactamases [5] and that clinical cefazolin failures associated with S.”
BackgroundFailure of Cephalosporins to Prevent Staphylococcus aureus Surgical Wound Infections
Kernodle, D. S., Classen, D. C., Burke, J. F., & Kaiser, A. B. (1990) · JAMA · doi:10.1001/jama.1990.03440070049031 · Cited by 97 · cited 1×
“aureus strains producing a large amount of type A b-lactamase [10, 20].”
Background
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Update on Infective Endocarditis
Bashore, T. M., Cabell, C., & Fowler, Jr. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2005.12.001 · Cited by 227
Nannini, E. C., Stryjewski, M. E., Singh, K. V., Bourgogne, A., Rude, T. H., Corey, G. R., Fowler, V. G., & Murray, B. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00317-09 · Cited by 160
“As previously reported (14), no increases in the cefazolin MIC at HI were observed with the Bla-negative strain ATCC 25923, while a slight increase (to 4 g/ml) was seen with the weak type A Bla producer ATCC 29213.”
BackgroundResultInfluentialSelf-citationLee, S., Choe, P. G., Song, K.-H., Park, S.-W., Kim, H. B., Kim, N. J., Kim, E.-C., Park, W. B., & Oh, M.-D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-11 · Cited by 128
“Among 4 identified Blas, type A Bla most efficiently hydrolyzes cefazolin (14).”
ResultInfluentialFernández Guerrero, M. L., González López, J. J., Goyenechea, A., Fraile, J., & de Górgolas, M. (2009) · Medicine · doi:10.1097/md.0b013e318194da65 · Cited by 121
“However, comparative studies on the efficacy of these drugs have never been conducted, and only anecdotal case reports have suggested a lesser activity of cefazolin in staphylococcal endocarditis.(53,128) The combination of cell-wall active compound with gentamicin increases the bactericidal activity of the regimen an…”
Li, J., Echevarria, K. L., Hughes, D. W., Cadena, J. A., Bowling, J. E., & Lewis, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02800-14 · Cited by 117
Miller, W. R., Seas, C., Carvajal, L. P., Díaz, L., Echeverri, A. M., Ferro, C., Ríos, R., Porras, P., Luna, C. M., Gotuzzo, E., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy123 · Cited by 116
“Our previous published data indicate that there is a strong association between the CzIE and relapses in deep-seated MSSA infections [17] and failure to eradicate MSSA from the bloodstream in patients undergoing hemodialysis [30].”
BackgroundSelf-citationRevest, M., Camou, F., Senneville, E., Caillon, J., Laurent, F. J., Calvet, B., Feugier, P., Batt, M., & Chidiac, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.014 · Cited by 124
Rao, S. N., Rhodes, N. J., Lee, B. J., Scheetz, M. H., Hanson, A. P., Segreti, J., Crank, C. W., & Wang, S. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04677-14 · Cited by 87
Bai, A. D., Showler, A., Burry, L. D., Steinberg, M., Ricciuto, D. R., Fernandes, T., Chiu, A., Raybardhan, S., Science, M. E., Fernando, E., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku560 · Cited by 82
Shao, Q., Zheng, Y. Q., Dong, X., Tang, K., Yan, X., & Xing, B. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201301654 · Cited by 64
Lee, S., Kwon, K. T., Kim, H. I., Chang, H., Lee, J., Choe, P. G., Park, W. B., Kim, N. J., Oh, M., Song, D. Y., et al. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2013.0229 · Cited by 64
Amodeo, M. R., Clulow, T., Lainchbury, J. G., Murdoch, D., Gallagher, K., Dyer, A., Metcalf, S. C. L., Pithie, A. D., & Chambers, S. T. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.09.009 · Cited by 64
Bard, J. D., Hindler, J. A., Gold, H. S., & Limbago, B. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu043 · Cited by 63
Ulloa, E. R., Singh, K. V., Geriak, M., Haddad, F. A., Murray, B. E., Nizet, V., & Sakoulas, G. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz995 · Cited by 60
Self-citationEljaaly, K., Alshehri, S. O., & Erstad, B. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01816-17 · Cited by 59
Livorsi, D. J., Crispell, E. K., Satola, S. W., Burd, E. M., Jerris, R. C., Wang, Y. F., & Farley, M. M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-12 · Cited by 59
“Southern blot hybridization (23) was performed to confirm the absence of the blaZ gene for strains that were negative by PCR on pulsed-field gel electrophoresis (PFGE) gels (17) that were probed with the 861-bp blaZ gene segment labeled with digoxigenin by PCR (Roche Diagnostics, Indianapolis, IN), according to the ma…”
BackgroundMethodInfluentialRincón, S., Reyes, J., Carvajal, L. P., Rojas, N., Cortés-Muñoz, F., Panesso, D., Guzman, M., Zurita, J., Adachi, J. A., Murray, B. E., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt254 · Cited by 58
Self-citationSakoulas, G., Olson, J., Yim, J., Singh, N. B., Kumaraswamy, M., Quach, D., Rybak, M. J., Pogliano, J., & Nizet, V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-16 · Cited by 60
Shao, Q., & Xing, B. (2011) · Chemical Communications · doi:10.1039/c1cc16165b · Cited by 57
Chong, Y. P., Park, S. ‐., Kim, E. S., Bang, K. M., Kim, M.-N., Kim, S., Lee, S.-O., Choi, S., Jeong, J.-Y., Woo, J. H., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2241-5 · Cited by 54
Li, J., Echevarria, K. L., & Traugott, K. A. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1892 · Cited by 52
Aw, J., Widjaja, F., Ding, Y., Mu, J., Liang, Y., & Xing, B. (2016) · Chemical Communications · doi:10.1039/c6cc09296a · Cited by 46
Nannini, E. C., Stryjewski, M. E., Singh, K. V., Rude, T. H., Corey, G. R., Fowler, V. G., & Murray, B. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01325-09 · Cited by 46
Self-citationWang, S. K., Gilchrist, A., Loukitcheva, A., Plotkin, B. J., Sigar, I. M., Gross, A. E., O’Donnell, J. N., Pettit, N. N., Buros, A. F., O’Driscoll, T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00382-18 · Cited by 45
“presented an aortic native valve endocarditis patient who presumably failed cefazolin therapy with a MSSA strain expressing the type A blaZ gene showing a significant rise in MIC, to 128 g/ml at HI (32).”
BackgroundSelf-citationBeganovic, M., Cusumano, J. A., Lopes, V., LaPlante, K. L., & Caffrey, A. R. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz270 · Cited by 44
“Although hydrolysis may be overcome in standard infections (ie, 5 × 10(5) CFU/mL), treatment failure in highinoculum infections (ie, >5 × 10(7) CFU/mL) has been described [27, 30, 31].”
BackgroundA review of current treatment strategies for infective endocarditis
Luque-Paz, D., Lakbar, I., & Tattevin, P. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822165 · Cited by 43
Rapid optical determination of β-lactamase and antibiotic activity
Khan, S., Sallum, U. W., Zheng, X., Nau, G. J., & Hasan, T. G. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-84 · Cited by 43
“The inoculum effect with different cephalosporins has been reported in clinical isolates of MSSA [33,36], and instances of clinical failure of cephalosporins are well documented in high-inoculum staphylococcal endocarditis infections and bacteremia [37-40].”
BackgroundRindone, J. P., & Mellen, C. K. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13554 · Cited by 40
Real-Time PCR Assay for Detection of blaZ Genes in Staphylococcus aureus Clinical Isolates
Pereira, L. A., Harnett, G. B., Hodge, M. M., Cattell, J. A., & Speers, D. J. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03413-13 · Cited by 37
“the gold standard for -lactamase detection when comparing phenotypic tests (6, 13, 16, 24, 25).”
MethodCefazolin Therapy for Staphylococcus aureus Bacteremia
Fernández-Guerrero, M. L., & Górgolas, M. (2005) · Clinical Infectious Diseases · doi:10.1086/430833 · Cited by 36
the Korea INfectious Diseases (KIND) study group, Song, K., Jung, S., Lee, S., Park, S., Kiem, S., Lee, S. H., Kwak, Y.-G., Ys, K., Jang, H.-C., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2799-1 · Cited by 35
“demonstrate the CIE with cefazolin [3, 5, 28].”
BackgroundInfluentialDingle, T. C., Gamage, D., Gomez-Villegas, S. I., Hanson, B., Reyes, J., Abbott, A., Burnham, C. D., Bard, J. D., Fritz, S. A., Miller, W. R., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02495-21 · Cited by 32
“Quality control was performed each day of testing by using three quality control strains: ATCC 29213 (BlaZ type A producer, CzIE negative), TX0117 (BlaZ type A producer, CzIE positive), and ATCC 25923 (BlaZ negative, CzIE negative) (19).”
Kaye, K. S. (2012) · Journal of Hospital Medicine · doi:10.1002/jhm.983 · Cited by 31
“One word of caution, however, is that there is some controversy over using cefazolin in patients with S aureus native valve endocarditis, given the possibility of a Type A b-lactamaseproducing species causing cefazolin degradation.(40) As a result, the clinician should first rule out endocarditis in the patient here b…”
BackgroundCarvajal, L. P., Rincón, S., Echeverri, A. M., Porras, J., Ríos, R., Ordóñez, K., Seas, C., Gomez-Villegas, S. I., Díaz, L., Arias, C. A., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02511-19 · Cited by 30
“CC30 was the predominant clone among isolates displaying CzIE, with 35% out of 253 of the isolates belonging to sequence type 30 (ST30).”
BackgroundInfluentialthe Korea INfectious Diseases (KIND) study group, Song, K., Jung, S., Lee, S., Park, S., Kim, E. S., Park, K., Park, W. B., Choe, P. G., Kim, Y. K., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3392-6 · Cited by 30
Lecomte, R., Bourreau, A., Deschanvres, C., Issa, N., Turnier, P. L., Gaborit, B. J., Chauveau, M., Leroy, A., Tourneau, T. L., Caillon, J., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.044 · Cited by 30
Genetic diversity and antibiotic susceptibility of Staphylococcus aureus isolates from wild boars
Seinige, D., von Altrock, A., & Kehrenberg, C. (2017) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2017.07.003 · Cited by 32
Allen, J. M., Bakare, L. S., Casapao, A. M., Klinker, K. P., Childs‐Kean, L. M., & Pomputius, A. F. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00259-4 · Cited by 29
Wi, Y. M., Park, Y. K., Moon, C., Ryu, S. Y., Lee, H., Ki, H. K., Cheong, H. S., Son, J. S., Lee, J. S., Kwon, K. T., et al. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.07.011 · Cited by 29
“A previous study reported cefazolin clinical failure in patients with serious MSSA infections due to high production of the type A β-lactamase (Nannini et al., 2003), and cefazolin was shown to be efficiently hydrolyzed by this enzyme (Zygmunt et al.”
BackgroundStaphylococcus aureus Bacteremia: Contemporary Management.
Abraham, L., & Bamberger, D. M. (2020) · Missouri medicine · Cited by 44
Saeki, M., Shinagawa, M., Yakuwa, Y., Nirasawa, S., Sato, Y., Yanagihara, N., & Takahashi, S. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.10.021 · Cited by 25
Influence of Reported Penicillin Allergy on Mortality in MSSA Bacteremia
Turner, N., Moehring, R. W., Sarubbi, C., Wrenn, R., Drew, R. H., Cunningham, C. K., Fowler, V. G., & Anderson, D. J. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy042 · Cited by 26
“The use of cefazolin carries with it some concerns based on a few case reports describing treatment failures, particularly in deep-seated MSSA infections, theoretically attributed to an inoculum effect [29, 30].”
BackgroundPresence and diversity of the β-lactamase gene in cat and dog staphylococci
Malik, S., Christensen, H. K., Peng, H., & BARTON, M. D. (2007) · Veterinary Microbiology · doi:10.1016/j.vetmic.2007.02.012 · Cited by 25
Winans, S. A., Luce, A. M., & Hasbun, R. (2013) · Infection · doi:10.1007/s15010-013-0477-0 · Cited by 26
“However, multiple studies have described cefazolin treatment failures when treating infections caused by MSSA, which has been linked to a production of large amounts of type A beta-lactamase [6, 7, 10].”
BackgroundBourreau, A., Mabecque, V. L., Broquet, A. H., & Caillon, J. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.09.021 · Cited by 23
Rincón, S., Carvajal, L. P., Gomez-Villegas, S. I., Echeverri, A. M., Ríos, R., Dinh, A. Q., Pedroza, C., Ordóñez, K., Nannini, E. C., Sun, Z., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01938-20 · Cited by 22
“Controls included S. aureus TX0117, a strain that harbors a type A BlaZ and exhibits the CzIE.”
BackgroundSelf-citationMartins-Silva, P., Dias, C. D. P., Vilar, L. C., Silva, S. D. Q., Rossi, C. C., & Marval, M. G.-D. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-24725-8 · Cited by 22
Singh, K. V., Tran, T. T., Nannini, E. C., Tam, V. H., Arias, C. A., & Murray, B. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-17 · Cited by 21
Self-citationLee, B. J., Wang, S. K., Constantino-Corpuz, J. K., Apolinario, K., Nadler, B., McDanel, J. S., Scheetz, M. H., & Rhodes, N. J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.013 · Cited by 20
Shuford, J. A., Piper, K. E., Hein, M. M., Trampuž, A., Steckelberg, J. M., & Patel, R. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.09.015 · Cited by 16
Lee, S. O., Lee, S., Park, S., Lee, J. E., & Lee, S. H. (2019) · Infection and Chemotherapy · doi:10.3947/ic.2019.51.4.376 · Cited by 15
“aureus ATCC 25923 (a β-lactamase negative strain) were used as controls [1, 22].”
BackgroundMethodLee, S. H., Park, W. B., Lee, S., Park, S., Kim, S., Lee, J., Chang, H., Kwon, K. T., Choe, P. G., Kim, N. J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01517-16 · Cited by 15
Guillemot, D., Bonacorsi, S., Blanchard, J. S., Weber, P., Simon, S., Guesnon, B., Bingen, É., & Carbon, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4618-4623.2004 · Cited by 15
Hidalgo, L. H., Muñóz, P., Álvarez‐Uría, A., Alonso, D., Márquez, R. L., Gutiérrez‐Carretero, E., Fariñas, M. C., Miró, J. M., Goenaga, M. Á., López-Cortés, L. E., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.10.019 · Cited by 12
Twilla, J. D., Algrim, A., Adams, E. H., Samarin, M. J., Cummings, C. D., & Finch, C. K. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.04.006 · Cited by 12
Miller, W. R., Singh, K. V., Arias, C. A., & Murray, B. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01158-18 · Cited by 11
“5 to 4 g/ml (below the 16 g/ml cutoff for the CzIE), while the cefazolin MIC for TX0117 was 128 g/ml, consistent with prior studies (10).”
BackgroundMethodSelf-citationMechanisms of Resistance to β-Lactam Antibiotics
Kernodle, D. S. (2014) · ASM Press eBooks · doi:10.1128/9781555816513.ch62 · Cited by 10
Su, Y., Hung, W., Lin, J.-M., Chang, C.-C., Chen, Y.-H., Lai, Y., Tseng, S., Lu, P., Yamamoto, T., Teng, L., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106047 · Cited by 10
Chen, M. M. S., Boardman, W., Smith, I., Goodman, A. E., & Brown, M. H. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.05.002 · Cited by 9
“As a supplement to primer pair 487–531, primers to amplify an 861 bp fragment (B861) of the bla region encompassing blaZ [11,13] were used on a limited number of isolates.”
MethodSakoulas, G., & Nizet, V. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.00366-23 · Cited by 10
Karchmer, A. W. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix288 · Cited by 9
Pliakos, E. E., Ziakas, P. D., & Mylonakis, E. E. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab476 · Cited by 8
Gomez-Villegas, S. I., Rincón, S., Carvajal, L. P., Matiz-González, J. M., Panesso, D., Tran, T. T., Flores, E. M., Dziadula, J., Baptista, R. P., Dingle, T. C., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf093 · Cited by 7
Hirai, J., Asai, N., Hagihara, M., Kishino, T., Kato, H., Sakanashi, D., Ohashi, W., & Mikamo, H. (2022) · Antibiotics · doi:10.3390/antibiotics11111505 · Cited by 7
Ceftobripole: Experience in staphylococcal bacteremia.
Soriano, À., & Morata, L. (2019) · PubMed Central · Cited by 7
Chan, L., Chan-Tompkins, N. H., Como, J., & Guarascio, A. J. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019897267 · Cited by 7
“Experimental MSSA endocarditis models have reported lower rates of bacterial eradication with cefazolin compared with nafcillin.(5) In addition, intermittent case reports of treatment failure have been reported with cefazolin use for the treatment of bacteremia and endocarditis.”
BackgroundLee, S. O., Lee, J. E., Park, S., Lee, J. E., & Lee, S. H. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf065 · Cited by 6
Winston, L. G., Deck, D. H., & Bolger, A. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50085-8 · Cited by 7
Trouillet‐Assant, S., Valour, F., Mouton, W., Martins-Simões, P., Lustıg, S., Laurent, F. J., & Ferry, T. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.11.013 · Cited by 6
“aureus was implicated in failure of cefazolin treatment, partly due to an inoculum effect, defined as significantly increased MIC with increasing bacterial density and mainly reported with type A β-lactamase (Nannini et al., 2003).”
BackgroundCefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus clinical isolates
Tsuji, S., Gotoh, K., Manabe, T., Iio, K., Fukushima, S., Matsushita, O., & Hagiya, H. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116399 · Cited by 5
Adema, J. L., Ahiskali, A., Fida, M., Hornback, K. M., Stevens, R. W., & Rivera, C. G. (2023) · Pathogens · doi:10.3390/pathogens12050703 · Cited by 6
Destrem, A.-L., Maillard, A., Simonet, M., Siméon, S., Contejean, A., Vignau, C., Pires, L., Isnard, M., Vitrat, V., Delory, T., et al. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04851-6 · Cited by 5
Wood, J. B., Newland, J. G., Thomsen, I. P., & Creech, C. B. (2016) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piw052 · Cited by 5
Gupta, R., Kaushal, V., Goyal, A., Kumar, P., Gupta, D., Tandon, R., Mahajan, A., Singla, S., Singh, G., Singh, B., et al. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.10.013 · Cited by 6
Medical treatment of endocarditis
Abrutyn, E., Cabell, C. H., Fowler, V. G., Hoen, B., Miró, J. M., Mestres, C. A., Sexton, D. J., & Corey, G. R. (2007) · Current Infectious Disease Reports · doi:10.1007/s11908-007-0043-y · Cited by 5
“Questions have been raised about the efficacy of cefazolin against S. aureus, but many if not most clinicians use cefazolin in the treatment of serious S. aureus infection, even though the overall significance of experimental findings [14] or reported treatment failures [ 15 ] is unknown.”
BackgroundTreatment of Native Valve Endocarditis: General Principles and Therapy for Specific Organisms
Vinh, D. C., & Embil, J. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-453-3_9 · Cited by 4
“Inoculum burden critically affects antibiotic activity [16,17] : within cardiac vegetations, bacteria may reach very high concentrations (108–1010 organisms per gram of tissue) [10,16].”
BackgroundFukushima, S., Tsuji, S., Gotoh, K., Iio, K., Ogawa, S., Koyanagi, N., Ito, Y., Koganemaru, H., Yoshida, A., & Hagiya, H. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117345 · Cited by 3
Pallasch, J., Takahashi, M., Taubert, K. A., Shulman, S. T., Burns, J. C., Falace, D. A., Newburger, J. W., Gewitz, H.-S., Tong, D., Steckelberg, J. M., et al. (2007) · Cited by 3
Khan, S. A., & Hasan, T. G. (2014) · Springer eBooks · doi:10.1007/978-3-642-39629-8_11 · Cited by 3
“This effect is observed most commonly with b-lactam antibiotics with b-lactamase producing bacteria, and can be a cause for treatment failures [84–90].”
BackgroundTreatment Protocols for Bacterial Endocarditis and Infection of Electrophysiologic Cardiac Devices
Stryjewski, M. E., & Corey, G. R. (2005) · CRC Press eBooks · doi:10.1201/9781420028232-30 · Cited by 4
Sales, M. J., Sakoulas, G., Szubin, R., Palsson, B. Ø., Arias, C. A., Singh, K. V., Murray, B. E., & Monk, J. M. (2020) · Microbiology Resource Announcements · doi:10.1128/mra.01515-19 · Cited by 3
Self-citationTreatment of Staphylococcal Infections
Crossley, K., & John, J. F. (2009) · Wiley eBooks · doi:10.1002/9781444308464.ch31 · Cited by 4
Bashore, T. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5892-2.00022-2 · Cited by 5
Lee, S., Park, S., Kim, J. N., Lee, S. O., Lee, J. E., & Lee, S. H. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01106-24 · Cited by 2
Disc Test for Detecting Staphylococcus aureus Strains Producing Type A and Type C β-Lactamases
George, C. R. R., Lahra, M. M., Nguyen, T., & Gatus, B. J. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00220-23 · Cited by 3
Carbon, silicon, germanium, tin and lead
Parr, J. (2012) · Annual Reports Section A (Inorganic Chemistry) · doi:10.1039/c2ic90021a · Cited by 2
Vinh, D. C., & Embil, J. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27784-4_9 · Cited by 2
Issues in the management of endocarditis caused by resistant gram-positive organisms
Stryjewski, M. E., Chu, V. H. Y., Cabell, C. H., & Fowler, V. G. (2004) · Current Infectious Disease Reports · doi:10.1007/s11908-004-0049-7 · Cited by 1
Biedenbach, D. J., Bouchillon, S. K., & Bezirtzoglou, E. (2015) · Cited by 1
Glycopeptide Antibacterials and the Treatment of Biofilm-Related Infections
Verna, R., Verhoef, J., & Pace, J. (2005) · CRC Press eBooks · doi:10.1201/9781420028232-27 · Cited by 1
Gatermann, S. G., & Kaase, M. (2008) · Journal of Laboratory Medicine · doi:10.1515/jlm.2008.042 · Cited by 1
Failure of Cefazolin in Staphylococcal Endocarditis
Ampel, N. M. (2003) · Journal watch · doi:10.1056/id200311240000002
Infective Endocarditis and Its Mimics inCriticalCare
Brusch, J. L. (2009) · Infectious disease and therapy · doi:10.3109/9781420080049.013
Staphylococcus aureus Bacteremia and Endocarditis
Kanafani, Z. A., Cosgrove, S. E., & Fowler, V. G. (2009) · Wiley eBooks · doi:10.1002/9781444308464.ch16
Infective Endocarditis and Its Mimics inCriticalCare
Brusch, J. L. (2009) · Infectious disease and therapy · doi:10.3109/9781420092417.013
Aw, J., Widjaja, F., Ding, Y., Mu, J., Yang, L., & Xing, B. (2017) · Chemical Communications · doi:10.1039/c7cc90354e
Natesan, R., Simon, M., Adam, I., Hernandez, G., Williford, S., Denquin, O., Pulcini, C., Thilly, N., & Lefèvre, B. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01765-25
Metadata
- Authors
- Nannini, E. C., Singh, K. V., & Murray, B. E.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murray, B. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 37
- Issue
- 9
- Pages
- 1194-1198
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137030105
- Cited by
- 103
- References
- 26
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 3 · 2012: 3
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- Staphylococcus aureus, native valve endocarditis, aortic valve endocarditis, cefazolin, beta-lactamase, antibiotic resistance, minimum inhibitory concentration, time-kill kinetics, beta-lactamase genes, antibiotic treatment failure
- MeSH terms
- Anti-Bacterial Agents, beta-Lactamases, Cefazolin, Endocarditis, Bacterial, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Recurrence, Staphylococcal Infections, Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.